A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients
PHASE3RecruitingINTERVENTIONAL
Enrollment
794
Participants
Timeline
Start Date
July 25, 2018
Primary Completion Date
June 15, 2023
Study Completion Date
December 31, 2028
Conditions
Breast Cancer
Interventions
DRUG
capecitabine
additional metronomic chemotherapy of capecitabine
Trial Locations (1)
510060
RECRUITING
Shusen Wang, Guangzhou
All Listed Sponsors
lead
Sun Yat-sen University
OTHER
NCT03561740 - A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients | Biotech Hunter | Biotech Hunter